TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: UVX as an Adjuvant in the Treatment of Fungal Keratitis
Brief Summary: In this study, investigators want to find the effect of adjuvant collagen cross-linking in the treatment of fungal keratitis


Options:
A: Arm Label: Riboflavin drops every minute; Type: ACTIVE_COMPARATOR; Interventions: Drug: Riboflavin | Arm Label: Riboflavin drops every 2 minutes; Type: ACTIVE_COMPARATOR; Interventions: Drug: Riboflavin | Intervention Type: DRUG; Name: Riboflavin; Assigned to Arm(s): Riboflavin drops every 2 minutes | Intervention Type: DRUG; Name: Riboflavin; Assigned to Arm(s): Riboflavin drops every minute
B: Arm Label: Collagen crosslinking group; Type: EXPERIMENTAL; Interventions: Procedure: collagen crosslinking group, Drug: Topical anti-fungal therapy | Arm Label: standard medical therapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Topical anti-fungal therapy | Intervention Type: PROCEDURE; Name: collagen crosslinking group; Assigned to Arm(s): Collagen crosslinking group | Intervention Type: DRUG; Name: Topical anti-fungal therapy; Assigned to Arm(s): Collagen crosslinking group, standard medical therapy
C: Arm Label: conventional treatment; Type: EXPERIMENTAL; Interventions: Drug: topical voriconazole / levofloxacin systemic itraconazole | Arm Label: conventional treatment +CXL; Type: ACTIVE_COMPARATOR; Interventions: Drug: topical voriconazole / levofloxacin systemic itraconazole, Radiation: CXL | Intervention Type: DRUG; Name: topical voriconazole / levofloxacin systemic itraconazole; Assigned to Arm(s): conventional treatment, conventional treatment +CXL | Intervention Type: RADIATION; Name: CXL; Assigned to Arm(s): conventional treatment +CXL
D: Arm Label: 30 minute light duration; Type: ACTIVE_COMPARATOR; Interventions: Drug: riboflavin, Device: UVX Light | Arm Label: 45 minute light duration; Type: ACTIVE_COMPARATOR; Interventions: Device: UVX Light | Intervention Type: DRUG; Name: riboflavin; Assigned to Arm(s): 30 minute light duration | Intervention Type: DEVICE; Name: UVX Light; Assigned to Arm(s): 30 minute light duration, 45 minute light duration

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Improving Older Adults' Decision Making for Obstructive Sleep Apnea Treatment (Phase 3)
Brief Summary: This study evaluates the feasibility of conducting a randomized controlled trial that tests a patient decision aid for obstructive sleep apnea in older adults with newly-diagnosed obstructive sleep apnea treated in an outpatient sleep clinic. Half of the participants will use a patient decision aid, while the other half will receive general information about sleep.


Options:
A: Arm Label: Patient decision aid; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Patient decision aid | Arm Label: General sleep education; Type: SHAM_COMPARATOR; Interventions: Behavioral: General sleep education | Intervention Type: BEHAVIORAL; Name: Patient decision aid; Assigned to Arm(s): Patient decision aid | Intervention Type: BEHAVIORAL; Name: General sleep education; Assigned to Arm(s): General sleep education
B: Arm Label: Deep Brain Stimulation; Type: EXPERIMENTAL; Interventions: Device: Deep Brain Stimulation | Intervention Type: DEVICE; Name: Deep Brain Stimulation; Assigned to Arm(s): Deep Brain Stimulation
C: Arm Label: MOMCare intervention; Type: EXPERIMENTAL; Interventions: Behavioral: MOMCare | Arm Label: Care Plus; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: MOMCare; Assigned to Arm(s): MOMCare intervention
D: Arm Label: Decision aid; Type: ACTIVE_COMPARATOR; Interventions: Other: Decision Aid | Arm Label: Normal care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Decision Aid; Assigned to Arm(s): Decision aid

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Nasal High Frequency Oscillation Ventilation(NHFOV) vs. Nasal Continuous Positive Airway Pressure(NCPAP) as Post-extubation Respiratory Support in Preterm Infants With Respiratory Distress Syndrome:a Randomized Controlled Trial
Brief Summary: In very preterm infants with severe respiratory distress syndrome(RDS), invasive ventilation(IV) , besides nasal continuous positive airway pressure (NCPAP) and early/selective pulmonary surfactant administration, is one key cornerstone to reduce neonatal mortality. However, IV is related to increased risks of bronchopulmonary dysplasia (BPD) and abnormal developmental outcomes in the survival.Weaning from IV is therefore a key procedure to reducing these risks above, and if extubation does not success, repeated intubation and/or prolonged duration of IV will result in increased medical burden and intubation-associated complications and death. How to minimize the need for endotracheal ventilation and subsequent complications constitutes a challenge for neonatologists.


Options:
A: Arm Label: nHFPV; Type: EXPERIMENTAL; Interventions: Procedure: Intrapulmonary Percussive Ventilation | Arm Label: nCPAP; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Nasal Continuous Positive Airway Pressure ventilation | Intervention Type: PROCEDURE; Name: Nasal Continuous Positive Airway Pressure ventilation; Assigned to Arm(s): nCPAP | Intervention Type: PROCEDURE; Name: Intrapulmonary Percussive Ventilation; Assigned to Arm(s): nHFPV
B: Arm Label: nCPAP; Type: ACTIVE_COMPARATOR; Interventions: Procedure: nasal continuous positive airway pressure (nCPAP) | Arm Label: nHFOV; Type: EXPERIMENTAL; Interventions: Procedure: noninvasive high-frequency ventilation (nHFOV) | Intervention Type: PROCEDURE; Name: noninvasive high-frequency ventilation (nHFOV); Assigned to Arm(s): nHFOV | Intervention Type: PROCEDURE; Name: nasal continuous positive airway pressure (nCPAP); Assigned to Arm(s): nCPAP
C: Arm Label: NHFOV; Type: EXPERIMENTAL; Interventions: Device: NHFOV | Arm Label: NCPAP; Type: ACTIVE_COMPARATOR; Interventions: Device: NCPAP | Intervention Type: DEVICE; Name: NHFOV; Assigned to Arm(s): NHFOV | Intervention Type: DEVICE; Name: NCPAP; Assigned to Arm(s): NCPAP
D: Arm Label: NHFOV; Type: EXPERIMENTAL; Interventions: Device: NHFOV | Arm Label: NCPAP; Type: ACTIVE_COMPARATOR; Interventions: Device: NCPAP | Arm Label: NIPPV; Type: EXPERIMENTAL; Interventions: Device: NIPPV | Intervention Type: DEVICE; Name: NHFOV; Assigned to Arm(s): NHFOV | Intervention Type: DEVICE; Name: NCPAP; Assigned to Arm(s): NCPAP | Intervention Type: DEVICE; Name: NIPPV; Assigned to Arm(s): NIPPV

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Lifespan Integration After Sexual Trauma, a Randomized Treatment Study
Brief Summary: A new psychological trauma treatment method is tested on a population (n 100) of adult women who have been sexually traumatized at one specific time 0-5 years before they enter the study.


Options:
A: Arm Label: Brief Cognitive Intervention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Brief Cognitive Therapy | Arm Label: Assessment Only; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Brief Cognitive Therapy; Assigned to Arm(s): Brief Cognitive Intervention
B: Arm Label: Written Exposure Therapy; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Written Exposure Therapy | Arm Label: Written Exposure Therapy Integrated with Cognitive Behavioral Therapy for Alcohol Use Disorder; Type: EXPERIMENTAL; Interventions: Behavioral: Written Exposure Therapy Integrated with Cognitive Behavioral Therapy for Alcohol Use Disorder | Intervention Type: BEHAVIORAL; Name: Written Exposure Therapy Integrated with Cognitive Behavioral Therapy for Alcohol Use Disorder; Assigned to Arm(s): Written Exposure Therapy Integrated with Cognitive Behavioral Therapy for Alcohol Use Disorder | Intervention Type: BEHAVIORAL; Name: Written Exposure Therapy; Assigned to Arm(s): Written Exposure Therapy
C: Arm Label: Lifespan Integration; Type: EXPERIMENTAL; Interventions: Other: Lifespan Integration | Arm Label: Waiting list; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Lifespan Integration; Assigned to Arm(s): Lifespan Integration
D: Arm Label: CBT for PTSD; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Cognitive Behavioral Therapy for PTSD | Arm Label: Imagery Rehearsal Therapy + CBT for PTSD; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive Behavioral Therapy for PTSD, Behavioral: Imagery Rehearsal Therapy | Intervention Type: BEHAVIORAL; Name: Cognitive Behavioral Therapy for PTSD; Assigned to Arm(s): CBT for PTSD, Imagery Rehearsal Therapy + CBT for PTSD | Intervention Type: BEHAVIORAL; Name: Imagery Rehearsal Therapy; Assigned to Arm(s): Imagery Rehearsal Therapy + CBT for PTSD

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Blood Pressure and Oxygenation Targets in Post-resuscitation Care, a Randomized Clinical Trial
Brief Summary: This study compares two blood pressure targets and two oxygenation targets in the post-resuscitation care of comatose out-of-hospital cardiac arrets patients. Using a novel method the blood pressure-intervention is double-blinded. The oxygenation-intervention is open-label. As a subordinate study, the patients will be randomized 1:1 to active fever-control with an automated feedback temperature control-device for 36 or 72 hours following return of spontaneous circulation.


Options:
A: Arm Label: Low normal MAP and low normal PaO2; Type: ACTIVE_COMPARATOR; Interventions: Other: Low normal MAP, Other: Low normal PaO2. | Arm Label: High normal MAP and low normal PaO2; Type: ACTIVE_COMPARATOR; Interventions: Other: High normal MAP, Other: Low normal PaO2. | Arm Label: Low normal MAP and high normal PaO2; Type: ACTIVE_COMPARATOR; Interventions: Other: Low normal MAP, Other: High normal PaO2 | Arm Label: High normal MAP and high normal PaO2; Type: ACTIVE_COMPARATOR; Interventions: Other: High normal MAP, Other: Low normal PaO2. | Intervention Type: OTHER; Name: Low normal MAP; Assigned to Arm(s): Low normal MAP and high normal PaO2, Low normal MAP and low normal PaO2 | Intervention Type: OTHER; Name: High normal MAP; Assigned to Arm(s): High normal MAP and high normal PaO2, High normal MAP and low normal PaO2 | Intervention Type: OTHER; Name: Low normal PaO2.; Assigned to Arm(s): High normal MAP and high normal PaO2, High normal MAP and low normal PaO2, Low normal MAP and low normal PaO2 | Intervention Type: OTHER; Name: High normal PaO2; Assigned to Arm(s): Low normal MAP and high normal PaO2
B: Arm Label: No oxygen; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Oxygen; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oxygen | Intervention Type: DRUG; Name: Oxygen; Assigned to Arm(s): Oxygen
C: Arm Label: Oxygenation, rigorous normal; Type: EXPERIMENTAL; Interventions: Drug: Oxygen | Arm Label: Oxygen, free conventional; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Oxygen; Assigned to Arm(s): Oxygenation, rigorous normal
D: Arm Label: Oxygen reduction; Type: EXPERIMENTAL; Interventions: Drug: Oxygen | Arm Label: Standard Care; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oxygen | Intervention Type: DRUG; Name: Oxygen; Assigned to Arm(s): Oxygen reduction, Standard Care

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Randomized, Open-Label Study of Nivolumab Combined With Cabozantinib Versus Sunitinib in Participants With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
Brief Summary: The purpose of this study is to determine whether Nivolumab Combined with Cabozantinib is safe and effective compared to Sunitinib in previously untreated advanced or metastatic renal cell carcinoma


Options:
A: Arm Label: Arm A: Nivolumab 3 mg/kg + Ipilimumab 1 mg/kg; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab, Biological: Ipilimumab | Arm Label: Arm B: Sunitinib 50 mg; Type: ACTIVE_COMPARATOR; Interventions: Biological: Nivolumab, Biological: Ipilimumab, Drug: Sunitinib | Intervention Type: BIOLOGICAL; Name: Nivolumab; Assigned to Arm(s): Arm A: Nivolumab 3 mg/kg + Ipilimumab 1 mg/kg, Arm B: Sunitinib 50 mg | Intervention Type: BIOLOGICAL; Name: Ipilimumab; Assigned to Arm(s): Arm A: Nivolumab 3 mg/kg + Ipilimumab 1 mg/kg, Arm B: Sunitinib 50 mg | Intervention Type: DRUG; Name: Sunitinib; Assigned to Arm(s): Arm B: Sunitinib 50 mg
B: Arm Label: Doublet; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab, Drug: Cabozantinib | Arm Label: Monotherapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sunitinib | Arm Label: Triplet; Type: EXPERIMENTAL; Interventions: Biological: Ipilimumab | Intervention Type: BIOLOGICAL; Name: Nivolumab; Assigned to Arm(s): Doublet | Intervention Type: DRUG; Name: Cabozantinib; Assigned to Arm(s): Doublet | Intervention Type: DRUG; Name: Sunitinib; Assigned to Arm(s): Monotherapy | Intervention Type: BIOLOGICAL; Name: Ipilimumab; Assigned to Arm(s): Triplet
C: Arm Label: A; Type: OTHER; Interventions: Drug: axitinib | Arm Label: B; Type: OTHER; Interventions: Drug: axitinib | Arm Label: C; Type: OTHER; Interventions: Drug: axitinib | Intervention Type: DRUG; Name: axitinib; Assigned to Arm(s): A | Intervention Type: DRUG; Name: axitinib; Assigned to Arm(s): B | Intervention Type: DRUG; Name: axitinib; Assigned to Arm(s): C
D: Arm Label: Arm A; Type: EXPERIMENTAL; Interventions: Drug: AMG 386, Drug: Sorafenib, Drug: AMG 386 placebo IV | Arm Label: Arm B; Type: EXPERIMENTAL; Interventions: Drug: AMG 386, Drug: Sorafenib | Arm Label: Arm C; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sorafenib, Drug: AMG 386 placebo IV | Intervention Type: DRUG; Name: AMG 386; Assigned to Arm(s): Arm A, Arm B | Intervention Type: DRUG; Name: Sorafenib; Assigned to Arm(s): Arm A, Arm B, Arm C | Intervention Type: DRUG; Name: AMG 386 placebo IV; Assigned to Arm(s): Arm A, Arm C

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Urinary Retention Rates After Immediate Removal of Foley Catheter Versus Backfill Void Trial Following Total Laparoscopic Hysterectomy: A Randomized Controlled Trial
Brief Summary: Acute urinary retention is a complication of hysterectomies that can result in bladder over-distension and long term bladder dysfunction. The incidence of acute urinary retention after total laparoscopic hysterectomy (TLH) has been reported to be anywhere between 4% and 34%. Studies have varied in the method of post-operative bladder challenge and the modality of hysterectomy included. Moreover, most of the published studies are retrospective chart reviews or prospective observational studies, with a lack of randomized controlled trials. Risk factors for urinary retention include type of anesthesia used, how the hysterectomy is performed, use of post-operative narcotics, pre-operative urinary retention, and possibly aggressive bladder dissection. With the increased trend towards same-day discharge following TLH, urinary retention may cause unnecessary patient distress and a worsened post-operative course. Standardization of post-hysterectomy bladder challenge and identification of risk factors for urinary retention may aid in preventing urinary retention or acute bladder dysfunction. The primary objective is to compare the rate of void trial failure after TLH with the backfill technique versus the autofill technique.


Options:
A: Arm Label: Autofill Void Trial; Type: ACTIVE_COMPARATOR; Interventions: Device: Void Trial using Foley catheter | Arm Label: Backfill Void Trial; Type: ACTIVE_COMPARATOR; Interventions: Device: Void Trial using Foley catheter | Intervention Type: DEVICE; Name: Void Trial using Foley catheter; Assigned to Arm(s): Autofill Void Trial, Backfill Void Trial
B: Arm Label: Study group 1; Type: EXPERIMENTAL; Interventions: Other: Removal of urethral catheter | Arm Label: Study group 2; Type: OTHER; Interventions: Other: Removal of urethral catheter | Intervention Type: OTHER; Name: Removal of urethral catheter; Assigned to Arm(s): Study group 1, Study group 2
C: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Tamsulosin | Intervention Type: DRUG; Name: Tamsulosin; Assigned to Arm(s): 2
D: Arm Label: Immediate catheter removal; Type: EXPERIMENTAL; Interventions: Procedure: Immediate catheter removal | Arm Label: Post op day 1 catheter removal; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Post op day 1 catheter removal | Intervention Type: PROCEDURE; Name: Immediate catheter removal; Assigned to Arm(s): Immediate catheter removal | Intervention Type: PROCEDURE; Name: Post op day 1 catheter removal; Assigned to Arm(s): Post op day 1 catheter removal

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Renal Effects of Remote Ischemic Preconditioning in Patients After Total Arch Replacement
Brief Summary: The purpose of this study is to test the hypothesis that remote ischemic preconditioning prevents acute kidney injury and improves clinical outcomes in patients undergoing total arch replacement.


Options:
A: Arm Label: Intervention; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Remote ischaemic preconditioning | Arm Label: Control; Type: SHAM_COMPARATOR; Interventions: Procedure: Control | Intervention Type: PROCEDURE; Name: Remote ischaemic preconditioning; Assigned to Arm(s): Intervention | Intervention Type: PROCEDURE; Name: Control; Assigned to Arm(s): Control
B: Arm Label: Remote ischaemic preconditioning; Type: EXPERIMENTAL; Interventions: Procedure: Remote ischaemic preconditioning | Arm Label: Control to remote preconditioning group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Remote ischaemic preconditioning; Assigned to Arm(s): Remote ischaemic preconditioning
C: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Procedure: clamping with pre-conditioning (PCl) | Arm Label: Arm 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: clamping with pre-conditioning (PCl); Assigned to Arm(s): Arm 1
D: Arm Label: RIPC intervention; Type: EXPERIMENTAL; Interventions: Other: remote ischemic preconditioning | Arm Label: Control; Type: SHAM_COMPARATOR; Interventions: Other: Control | Intervention Type: OTHER; Name: remote ischemic preconditioning; Assigned to Arm(s): RIPC intervention | Intervention Type: OTHER; Name: Control; Assigned to Arm(s): Control

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized, Multicentric, Open Label, Parallel Group Trial to Compare the Efficacy of 6-months Versus 3-months Therapy With Prednisolone for the First Episode of Idiopathic Nephrotic Syndrome in Children Younger Than 4 Years
Brief Summary: This study is a multicentric, randomized, parallel group, open label controlled trial of children age 1 year up to 4 years with new onset, idiopathic nephrotic syndrome. It is designed to test the initial duration of steroid therapy of either 3 month or 6 month total duration. Participants will be randomized to either extend their pre-trial 3 months (12 weeks) of standard of care corticosteroid therapy to add an additional 12 weeks of therapy or to stop therapy. Pre-trial standard of care corticosteroids will include 60 mg/m2/day for 6 weeks followed by 40 mg/m2/day every other day for 6 weeks of prednisolone or equivalent. The trial intervention will therefore be an additional 12 vs 0 weeks of corticosteroids in these children with idiopathic nephrotic syndrome.


Options:
A: Arm Label: B-Experimental; Type: EXPERIMENTAL; Interventions: Drug: acid mycophenolic (Myfortic) | Arm Label: A-Active Comparator; Type: ACTIVE_COMPARATOR; Interventions: Drug: Prednisone | Intervention Type: DRUG; Name: Prednisone; Assigned to Arm(s): A-Active Comparator | Intervention Type: DRUG; Name: acid mycophenolic (Myfortic); Assigned to Arm(s): B-Experimental
B: Arm Label: High dose prednisolone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Prednisolone | Arm Label: Alfacalcidol and low dose prednisolone; Type: EXPERIMENTAL; Interventions: Drug: Prednisolone, Drug: Alfacalcidol | Intervention Type: DRUG; Name: Prednisolone; Assigned to Arm(s): Alfacalcidol and low dose prednisolone, High dose prednisolone | Intervention Type: DRUG; Name: Alfacalcidol; Assigned to Arm(s): Alfacalcidol and low dose prednisolone
C: Arm Label: Intervention: Prednisolone; Type: EXPERIMENTAL; Interventions: Drug: Prednisolone | Arm Label: No intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Prednisolone; Assigned to Arm(s): Intervention: Prednisolone
D: Arm Label: prednisone 60 mg/meter square Body Surface Aera; Type: ACTIVE_COMPARATOR; Interventions: Drug: prednisone 60 mg/meter square Body Surface Area | Arm Label: prednisone 45 mg/meter square BSA; Type: ACTIVE_COMPARATOR; Interventions: Drug: prednisone 45 mg | Arm Label: prednisone 30 mg/meter squer BSA; Type: ACTIVE_COMPARATOR; Interventions: Drug: prednisone 30 mg | Intervention Type: DRUG; Name: prednisone 60 mg/meter square Body Surface Area; Assigned to Arm(s): prednisone 60 mg/meter square Body Surface Aera | Intervention Type: DRUG; Name: prednisone 45 mg; Assigned to Arm(s): prednisone 45 mg/meter square BSA | Intervention Type: DRUG; Name: prednisone 30 mg; Assigned to Arm(s): prednisone 30 mg/meter squer BSA

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Use of Vibration to Improve Visual/Spatial Neglect in Patients Affected by Stroke
Brief Summary: This study will measure if five minutes of vibration to the upper back neck muscles, prior to standard of care treatment, will improve symptoms of spatial neglect and/or activities of daily living function for patients who have had a stroke.


Options:
A: Arm Label: TMS and trunk rotation; Type: EXPERIMENTAL; Interventions: Device: TMS and trunk rotation | Arm Label: Sham TMS and trunk rotation; Type: SHAM_COMPARATOR; Interventions: Device: Sham TMS and trunk rotation | Intervention Type: DEVICE; Name: TMS and trunk rotation; Assigned to Arm(s): TMS and trunk rotation | Intervention Type: DEVICE; Name: Sham TMS and trunk rotation; Assigned to Arm(s): Sham TMS and trunk rotation
B: Arm Label: Vibration to upper posterior neck muscles; Type: EXPERIMENTAL; Interventions: Other: Vibration to upper posterior neck muscles | Arm Label: Standard of care; Type: ACTIVE_COMPARATOR; Interventions: Other: Standard of Care | Intervention Type: OTHER; Name: Vibration to upper posterior neck muscles; Assigned to Arm(s): Vibration to upper posterior neck muscles | Intervention Type: OTHER; Name: Standard of Care; Assigned to Arm(s): Standard of care
C: Arm Label: r-TMS Group; Type: EXPERIMENTAL; Interventions: Device: r-TMS | Arm Label: Sham Group; Type: SHAM_COMPARATOR; Interventions: Device: SHAM | Intervention Type: DEVICE; Name: r-TMS; Assigned to Arm(s): r-TMS Group | Intervention Type: DEVICE; Name: SHAM; Assigned to Arm(s): Sham Group
D: Arm Label: Virtual Environment feedback; Type: EXPERIMENTAL; Interventions: Device: Virtual Environment Biofeedback | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Device: Treadmill walking with no Virtual Environment Biofeedback | Intervention Type: DEVICE; Name: Virtual Environment Biofeedback; Assigned to Arm(s): Virtual Environment feedback | Intervention Type: DEVICE; Name: Treadmill walking with no Virtual Environment Biofeedback; Assigned to Arm(s): Control

Answer: B